Prognostic Implications of Tripartite Motif Containing 24 Expression Levels in Patients with Solid Tumors: A Systematic Review and Meta-Analysis
Yuan He(Xuzhou Medical College), Jian‐Yong Shao(Sun Yat-sen University), Man-Jun Luo(Nanfang Hospital), Tao Tang(Central South University), Changxuan You(Southern Medical University), Li‐Yue Sun(Sun Yat-sen University), Zu‐Lu Ye(Sun Yat-sen University), Kunwei Peng(Sun Yat-sen University Cancer Center), Ling Deng(Sun Yat-sen University)
Cited by 5
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation
|Cellular Physiology and Biochemistry|2018|294